Filing Flows › Comparisons › TRAW vs EVFM
Traws Pharma vs Evofem Biosciences: TRAW and EVFM compared
Traws Pharma is the larger company: $2.7M of revenue in its latest quarter (Q2 2025) against $2.6M for Evofem Biosciences (Q2 2026). Traws Pharma is growing faster (48× against -45% a year earlier). Traws Pharma is more profitable, with an operating margin of -45.7% against -94.5%.
Where the money goes: TRAW and EVFM
Traws Pharma (TRAW) · Q2 2025
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%, net loss $915K, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Evofem Biosciences (EVFM) · Q2 2026
Evofem Biosciences, Q2 2026: revenue $2.6M (-45% year over year), operating margin -94.5%, net loss $11.0M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Traws Pharma (TRAW) | Evofem Biosciences (EVFM) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q2 2026 |
| Revenue | $2.7M | $2.6M |
| Revenue growth, Y/Y | 48× | -45% |
| Operating margin | -45.7% | -94.5% |
| Net earnings | −$915K | −$11.0M |
| Net margin | -33.5% | -419.1% |
| Operating cash flow | −$6.0M | −$3.1M |
Questions
Which is bigger, Traws Pharma or Evofem Biosciences?
Traws Pharma is the larger company: $2.7M of revenue in its latest quarter (Q2 2025) against $2.6M for Evofem Biosciences (Q2 2026).
Is Traws Pharma or Evofem Biosciences growing faster?
Traws Pharma is growing faster (48× against -45% a year earlier).
Which is more profitable, Traws Pharma or Evofem Biosciences?
Traws Pharma is more profitable, with an operating margin of -45.7% against -94.5%.
More: Traws Pharma earnings · how Traws Pharma makes money · Evofem Biosciences earnings · how Evofem Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2025; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.